The Chinese first-episode schizophrenia trial: Background and study design

East Asian Archives of Psychiatry

Volumn 24, Issue 4, 2014, Pages 169-173

  Han, X ^a   Yuan, Y B ^a   Yu, X ^a   Zhao, J P ^b   Wang, C Y ^c   Lu, Z ^d   Yang, F D ^e   Dong, H ^f   Wu, Y F ^g   Ungvari, G S ^h   Xiang, Y T ⁱ   Chiu, H F K ^j  

^a PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e BEIJING HUILONGGUAN HOSPITAL   (China)

^f SICHUAN UNIVERSITY   (China)

^g PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^h Notre Dame University   (Australia)

ⁱ University of Macau   (Macao)

^j CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

more..

Author keywords

Antipsychotic agents; Clinical trial; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG TOLERABILITY; FIRST EPISODE SCHIZOPHRENIA; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT COMPLIANCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SOCIAL DISABILITY; STUDY DESIGN; ADOLESCENT; ADULT; CHINA; CLINICAL TRIAL; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHINA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PIPERAZINES; QUINOLONES; RESEARCH DESIGN; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84921722095     PISSN: 20789947     EISSN: 22247041     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Penttilä M, Miettunen J, Koponen H, Kyllonen M, Veijola J, Isohanni M, et al. Association between the duration of untreated psychosis and short- and long-term outcome in schizophrenia within the Northern Finland 1966 Birth Cohort. Schizophr Res 2013;143:3-10
2. Chang WC, Hui CL, Tang JY, Wong GH, Chan SK, Lee EH, et al. Impacts of duration of untreated psychosis on cognition and negative symptoms in first-episode schizophrenia: a 3-year prospective followup study. Psychol Med 2013;43:1883-93.
3. Volavka J, Czobor P, Derks EM, Bitter I, Libiger J, Kahn RS, et al. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry 2011;72:955-61.
4. Koranek AM, Smith TL, Mican LM, Rascati KL. Impact of the CATIE trial on antipsychotic prescribing patterns at a state psychiatric facility. Schizophr Res 2012;137:137-40.
5. Larson MK, Walker EF, Compton MT. Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. Expert Rev Neurother 2010;10:1347-59
6. Phillips MR. Characteristics, experience, and treatment of schizophrenia in China. Dialogues Clin Neurosci 2001;3:109-19.
7. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005;6:132-91.
8. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008;100:20-38.
9. Fleischhacker WW, Derks E, Kahn RS. Interpreting treatment trials in schizophrenia patients: lessons learned from EUFEST. Schizophr Res 2012;138:39-40
10. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia, a meta-analysis. Lancet 2009;373:31-41.
11. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a metaanalysis of randomized controlled trials. Schizophr Bull 2009;35:443-57.
12. Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia J Clin Psychopharmacol 1995;15(1 Suppl 1):45S-51S.
13. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al. Effectiveness and cost of olanzapine and halopendol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290:2693-702.
14. Akhondzadeh S, Safarcherati A, Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:253-9.
15. Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005;162:130-6.
16. Moller HJ, Riedel M, Jager M, Wickelmaier F, Maier W, Kuhn KU, et al Short-term treatment with risperidone or haloperidol in firstepisode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol 2008;11:985-97
17. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on Quality of Life of secondvs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87.
18. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
19. Si TM, Yang JZ, Shu L, Wang XL, Kong QM, Zhou M, et al. The reliability, validity of PANSS and its implication [in Chinese]. Chin Ment Health J 2004;18:45-7.
20. Guy W. Clinical global impressions, in ECDEU assessment manual for psychopharmacology (revised). Rockville, US National Institute of Mental Health; 1976:217-21.
21. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100.
22. Nielsen RE, Lindstrom E, Nielsen J, Levander S. DAI-10 is as good as DAI-30 in schizophrenia. Eur Neuropsychopharmacol 2012;22:747-50.
23. Cheng HL, Yu YW. Validation of the Chinese version of "the Drug Attitude Inventory" [in Chinese]. Kaohsiung J Med Sci 1997;13:370-7.
24. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-83.
25. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000;101 323-9.
26. Si TM, Shu L, Tian CH, Sun YA, Yan J, Cheng J, et al. Evaluation of reliability and validity of the Chinese version of Personal and Evaluation of Social Performance Scale in patients with schizophrenia Lin Chinese!. Chin Ment Health J 2009;23:790-4.
27. Shi C, Yu X, Wu ZY, Robert KH, Jin H, Thomas DM, et al. Neuropsychological feasibility study among HIV+/AIDS subjects in China, [in Chinese] Chin Ment Health J 2005;19:343-5.
28. Nuechterlem KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS Consensus Cognitive Battery, part 1 test selection, reliability, and validity. Am J Psychiatry 2008;165:203-13.
29. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, et al. The MATRICS Consensus Cognitive Battery, part 2: conorming and standardization. Am J Psychiatry 2008;165:214-20.